Tuesday, October 12, 2021
Axcella Health Inc. (AXLA)
Fifty Ways To Love Your Liver
Axcella Health Inc. is a clinical-stage biotechnology company focused on treating complex diseases and improvinge health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company’s pipeline includes two lead therapeutic candidates:, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy (OHE) , and AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH).
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Initiating Coverage of AXLA. Axcella Health is developing drugs based on endogenous metabolic modulators (EMMs), naturally occurring molecules that act as regulators and control mechanisms for metabolic pathways. Its two lead products are AXA1655, in a Phase 2 trial for overt hepatic encephalopathy (OHE), and AXA1125 in a Phase 2b trial for non-alcoholic steatohepatitis (NASH). Additional pipeline developments are expected before year end.
Axcella’s Products Target Multiple Pathways of Disease. The company’s EMM products are amino acid compositions in proprietary ratios that act through metabolic pathways. The indications in clinical trials are conditions in which liver disease or injury has starting a cycle of injury, repair, compromised function, and further injury. Axcella’s products work through the biological pathways to restore …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
